hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of ‘MET-addicted’ cancers
Abstract Background The tyrosine kinase receptor encoded by the MET oncogene is a major player in cancer. When MET is responsible for the onset and progression of the transformed phenotype (MET-addicted cancers), an efficient block of its oncogenic activation results in potent tumor growth inhibitio...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-03-01
|
| Series: | Journal of Experimental & Clinical Cancer Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13046-022-02320-6 |
| _version_ | 1811272262869843968 |
|---|---|
| author | Ilaria Martinelli Chiara Modica Cristina Chiriaco Cristina Basilico James M. Hughes Simona Corso Silvia Giordano Paolo M. Comoglio Elisa Vigna |
| author_facet | Ilaria Martinelli Chiara Modica Cristina Chiriaco Cristina Basilico James M. Hughes Simona Corso Silvia Giordano Paolo M. Comoglio Elisa Vigna |
| author_sort | Ilaria Martinelli |
| collection | DOAJ |
| description | Abstract Background The tyrosine kinase receptor encoded by the MET oncogene is a major player in cancer. When MET is responsible for the onset and progression of the transformed phenotype (MET-addicted cancers), an efficient block of its oncogenic activation results in potent tumor growth inhibition. Methods Here we describe a molecular engineered MET antibody (hOA-DN30) and validate its pharmacological activity in MET-addicted cancer models in vitro and in vivo. Pharmacokinetics and safety profile in non-human primates have also been assessed. Results hOA-DN30 efficiently impaired MET activation and the intracellular signalling cascade by dose and time dependent removal of the receptor from the cell surface (shedding). In vitro, the antibody suppressed cell growth by blocking cell proliferation and by concomitantly inducing cell death in multiple MET-addicted human tumor cell lines. In mice xenografts, hOA-DN30 induced an impressive reduction of tumor masses, with a wide therapeutic window. Moreover, the antibody showed high therapeutic efficacy against patient-derived xenografts generated from MET-addicted gastric tumors, leading to complete tumor regression and long-lasting effects after treatment discontinuation. Finally, hOA-DN30 showed a highly favorable pharmacokinetic profile and substantial tolerability in Cynomolgus monkeys. Conclusions hOA-DN30 unique ability to simultaneously erase cell surface MET and release the ‘decoy’ receptor extracellular region results in a paramount MET blocking action. Its remarkable efficacy in a large number of pre-clinical models, as well as its pharmacological features and safety profile in non-human primates, strongly envisage a successful clinical application of this novel single-arm MET therapeutic antibody for the therapy of MET-addicted cancers. |
| first_indexed | 2024-04-12T22:37:13Z |
| format | Article |
| id | doaj.art-5300d21aef514f059e95f9114917da72 |
| institution | Directory Open Access Journal |
| issn | 1756-9966 |
| language | English |
| last_indexed | 2024-04-12T22:37:13Z |
| publishDate | 2022-03-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Experimental & Clinical Cancer Research |
| spelling | doaj.art-5300d21aef514f059e95f9114917da722022-12-22T03:13:49ZengBMCJournal of Experimental & Clinical Cancer Research1756-99662022-03-0141111710.1186/s13046-022-02320-6hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of ‘MET-addicted’ cancersIlaria Martinelli0Chiara Modica1Cristina Chiriaco2Cristina Basilico3James M. Hughes4Simona Corso5Silvia Giordano6Paolo M. Comoglio7Elisa Vigna8Candiolo Cancer Institute, FPO-IRCCSCandiolo Cancer Institute, FPO-IRCCSCandiolo Cancer Institute, FPO-IRCCSCandiolo Cancer Institute, FPO-IRCCSCandiolo Cancer Institute, FPO-IRCCSCandiolo Cancer Institute, FPO-IRCCSCandiolo Cancer Institute, FPO-IRCCSCandiolo Cancer Institute, FPO-IRCCSCandiolo Cancer Institute, FPO-IRCCSAbstract Background The tyrosine kinase receptor encoded by the MET oncogene is a major player in cancer. When MET is responsible for the onset and progression of the transformed phenotype (MET-addicted cancers), an efficient block of its oncogenic activation results in potent tumor growth inhibition. Methods Here we describe a molecular engineered MET antibody (hOA-DN30) and validate its pharmacological activity in MET-addicted cancer models in vitro and in vivo. Pharmacokinetics and safety profile in non-human primates have also been assessed. Results hOA-DN30 efficiently impaired MET activation and the intracellular signalling cascade by dose and time dependent removal of the receptor from the cell surface (shedding). In vitro, the antibody suppressed cell growth by blocking cell proliferation and by concomitantly inducing cell death in multiple MET-addicted human tumor cell lines. In mice xenografts, hOA-DN30 induced an impressive reduction of tumor masses, with a wide therapeutic window. Moreover, the antibody showed high therapeutic efficacy against patient-derived xenografts generated from MET-addicted gastric tumors, leading to complete tumor regression and long-lasting effects after treatment discontinuation. Finally, hOA-DN30 showed a highly favorable pharmacokinetic profile and substantial tolerability in Cynomolgus monkeys. Conclusions hOA-DN30 unique ability to simultaneously erase cell surface MET and release the ‘decoy’ receptor extracellular region results in a paramount MET blocking action. Its remarkable efficacy in a large number of pre-clinical models, as well as its pharmacological features and safety profile in non-human primates, strongly envisage a successful clinical application of this novel single-arm MET therapeutic antibody for the therapy of MET-addicted cancers.https://doi.org/10.1186/s13046-022-02320-6MET oncogeneTargeted therapyAntibodyGastric cancer |
| spellingShingle | Ilaria Martinelli Chiara Modica Cristina Chiriaco Cristina Basilico James M. Hughes Simona Corso Silvia Giordano Paolo M. Comoglio Elisa Vigna hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of ‘MET-addicted’ cancers Journal of Experimental & Clinical Cancer Research MET oncogene Targeted therapy Antibody Gastric cancer |
| title | hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of ‘MET-addicted’ cancers |
| title_full | hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of ‘MET-addicted’ cancers |
| title_fullStr | hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of ‘MET-addicted’ cancers |
| title_full_unstemmed | hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of ‘MET-addicted’ cancers |
| title_short | hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of ‘MET-addicted’ cancers |
| title_sort | hoa dn30 a highly effective humanized single arm met antibody inducing remission of met addicted cancers |
| topic | MET oncogene Targeted therapy Antibody Gastric cancer |
| url | https://doi.org/10.1186/s13046-022-02320-6 |
| work_keys_str_mv | AT ilariamartinelli hoadn30ahighlyeffectivehumanizedsinglearmmetantibodyinducingremissionofmetaddictedcancers AT chiaramodica hoadn30ahighlyeffectivehumanizedsinglearmmetantibodyinducingremissionofmetaddictedcancers AT cristinachiriaco hoadn30ahighlyeffectivehumanizedsinglearmmetantibodyinducingremissionofmetaddictedcancers AT cristinabasilico hoadn30ahighlyeffectivehumanizedsinglearmmetantibodyinducingremissionofmetaddictedcancers AT jamesmhughes hoadn30ahighlyeffectivehumanizedsinglearmmetantibodyinducingremissionofmetaddictedcancers AT simonacorso hoadn30ahighlyeffectivehumanizedsinglearmmetantibodyinducingremissionofmetaddictedcancers AT silviagiordano hoadn30ahighlyeffectivehumanizedsinglearmmetantibodyinducingremissionofmetaddictedcancers AT paolomcomoglio hoadn30ahighlyeffectivehumanizedsinglearmmetantibodyinducingremissionofmetaddictedcancers AT elisavigna hoadn30ahighlyeffectivehumanizedsinglearmmetantibodyinducingremissionofmetaddictedcancers |